BKGI.BK Bangkok Genomics Innovation Pcl
- Market cap
- THB 1.38B
- P/E
- 14.4x
- P/B
- 2.36x
- ROE
- 21.3%
- Dividend yield
- 2.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BKGI.BK undervalued?
Graham numberBKGI.BK trades 22.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bangkok Genomics Innovation Pcl fundamental analysis
No fundamental analysis for Bangkok Genomics Innovation Pcl yet.
Bangkok Genomics Innovation Pcl stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bangkok Genomics Innovation Pcl
Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited …
Full company profileBangkok Genomics Innovation Pcl financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bangkok Genomics Innovation Pcl annual financial statements (THB; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 70.7M | 119M | 134M | 379M | 305M | 245M | 338M | 380M | 615M |
| Gross Profit | 4.48M | 34.3M | 35.5M | 165M | 154M | 116M | 140M | 150M | 250M |
| Operating Income | -13.9M | 12.7M | 13.8M | 106M | 64.4M | 32.8M | 53.8M | 42.4M | 137M |
| EBITDA | -13.8M | 15.5M | 21.7M | 115M | 94.3M | 49.5M | 70.2M | 63.9M | 162M |
| Net Income | -13.8M | 15.5M | 13.8M | 106M | 75.1M | 32.1M | 50.2M | 45.3M | 124M |
| EPS | -0.09 | 0.10 | 0.09 | 0.66 | 0.13 | 0.05 | 0.09 | 0.08 | 0.21 |
| Balance Sheet | |||||||||
| Total Assets | 58.8M | 53.2M | 97.9M | 188M | 301M | 293M | 608M | 702M | 743M |
| Total Liabilities | 43.0M | 21.8M | 54.3M | 38.5M | 52.9M | 57.2M | 68.4M | 149M | 156M |
| Shareholders' Equity | 15.9M | 31.4M | 43.6M | 149M | 248M | 236M | 537M | 551M | 584M |
| Cash & Short-term Investments | 8.40M | 8.94M | 11.7M | 50.7M | 148M | 166M | 390M | 222M | 133M |
| Total Debt | - | - | 13.2M | 10.6M | 31.6M | 23.7M | 24.0M | 21.5M | - |
| Cash Flow | |||||||||
| Operating Cash Flow | - | - | 12.7M | 55.6M | 81.2M | 71.8M | -3.50M | -88.2M | 142M |
| Capital Expenditure | - | - | 2.10M | 13.5M | 28.2M | 4.82M | 20.0M | 36.3M | 34.7M |
| Free Cash Flow | - | - | 10.5M | 42.2M | 53.0M | 66.8M | -23.5M | -124M | 107M |
| Ratios | |||||||||
| ROE | -86.7% | 49.4% | 31.6% | 70.8% | 30.3% | 13.6% | 9.3% | 8.2% | 21.3% |
| ROA | -23.4% | 29.2% | 14.1% | 56.3% | 25.0% | 11.0% | 8.3% | 6.5% | 16.7% |
| Net Profit Margin | -19.4% | 13.0% | 10.3% | 27.9% | 24.6% | 13.1% | 14.9% | 11.9% | 20.2% |
| Debt to Equity | - | - | 0.30x | 0.07x | 0.13x | 0.10x | 0.04x | 0.04x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bangkok Genomics Innovation Pcl dividends
- Dividend yield
- 2.03%
- Forward dividend
- 0.05 THB
- Payout ratio
- 61.9%
- Ex-dividend date
- May 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | THB 28.1M | 0.05 | 61.9% |
| 2024 | - | - | - |
| 2023 | THB 44.0M | 0.07 | 136.9% |
| 2022 | THB 167M | 0.28 | 221.7% |
| 2021 | - | - | - |
| 2020 | THB 1.73M | 0.01 | 12.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bangkok Genomics Innovation Pcl
- Insiders 69.56%
- Institutions 0.00%
- Public & others 30.44%
- Shares outstanding 600M
- Free float 250M
Bangkok Genomics Innovation Pcl company profile
- Company name
- Bangkok Genomics Innovation Pcl
- Ticker
- BKGI.BK
- Exchange
- Thailand Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- December
- Address
- 3689 Rama 4 Road, Bangkok, Thailand, 10110
- Phone
- 66 2 261 2638
- Website
- bangkokgenomics.com
About Bangkok Genomics Innovation Pcl
Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's genetics, and provide treatment and disease prevention. In addition, the company offers genetic analysis using whole exome sequencing, a technology that can detect gene abnormalities that cause diseases; individual genetic decoding, which involves detailed genetic sequencing to analyze genetic information and identify aspects such as ethnicity or ancestry, optimal exercise profiles, metabolic capabilities, and the risk of genetic diseases; newborn screening; and health check-ups for various needs. Further, it supports research services in both medical and other fields, offers DNA and RNA sequencing, metabolomics and proteomics services, and medical products comprising genetic sequencers; NIPT, PGT-A, hereditary cancer screening, and precision oncology solutions; real-time PCR that includes beta thalassemia genotyping and human papillomavirus genotyping kits; and cell-free DNA storage tubes. The company serves government sectors such as medical schools and health centers, as well as private sectors such as clinics, hospitals, private medical laboratories, research institutes, and universities. Bangkok Genomics Innovation Public Company Limited was founded in 2017 and is headquartered in Bangkok, Thailand.
Bangkok Genomics Innovation Pcl management
7- Dr. Saowalak DansakulCEO & Director · born 2000
- Mr. Sujie CaoExecutive Director · born 1987
- Mr. Xiaohan WangDeputy CEO, Acting Chief Business Officer & Director · born 1991
- Mr. Preecha LaohapongchanaExecutive Director · born 1955
- Mr. Kittikun Rod Rang NokChief Financial Officer · born 1991
- Mr. Porntep TanyutChief Operating Officer · born 1987
- Ms. Puttarawicha Mhankidcompany secretary